-
公开(公告)号：US20210340544A1
公开(公告)日：2021-11-04
申请号：US17286209
申请日：2019-10-18
IPC分类号： C12N15/117 , A61K45/06 , C07K16/28
摘要： The present disclosure relates to methods for treating cancer in patients having low expression of MHC Class I genes, and in patients having increased serum levels of PD-L2 by administration of a TLR9 agonist.
-
2.发明授权Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response 有权免疫调节寡核苷酸（IRO）化合物调节基于类似受体的免疫应答公开(公告)号：US09540651B2
公开(公告)日：2017-01-10
申请号：US14791749
申请日：2015-07-06
IPC分类号： A61K31/7115 , C12N15/117 , A61K45/06
CPC分类号： C12N15/117 , A61K31/7115 , A61K31/7125 , A61K45/06 , C12N2310/17 , C12N2310/31 , C12N2310/317 , C12N2310/321 , C12N2310/3341 , C12N2310/336 , C12N2310/51 , C12N2310/52 , Y02A50/401 , Y02A50/411 , Y02A50/414 , A61K2300/00
摘要： The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
摘要翻译： 本发明提供作为TLR拮抗剂的新型免疫调节寡核苷酸（IRO）及其使用方法。 这些IRO具有独特的序列，其响应于TLR配体或TLR激动剂抑制或抑制TLR介导的信号传导。 该方法可用于预防和治疗癌症，自身免疫性疾病，气道炎症，炎症性疾病，感染性疾病，皮肤病，变态反应，哮喘或由病原体引起的疾病。
-
公开(公告)号：US09206430B2
公开(公告)日：2015-12-08
申请号：US13731492
申请日：2012-12-31
发明人： Ekambar R. Kandimalla , Daqing Wang , Yukui Li , Dong Yu , FuGang Zhu , Lakshmi Bhagat , Sudhir Agrawal
IPC分类号： C12N15/117 , A61K48/00 , A61K39/00
CPC分类号： C12N15/117 , A61K9/0019 , A61K31/713 , A61K45/06 , A61K48/00 , A61K2039/55561 , C12N2310/17 , C12N2310/314 , C12N2310/321 , C12N2310/33 , C12N2310/335 , C12N2320/31
摘要： The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
-
公开(公告)号：US09096858B2
公开(公告)日：2015-08-04
申请号：US13905242
申请日：2013-05-30
IPC分类号： C12N15/117 , A61K31/7115 , A61K45/06
CPC分类号： C12N15/117 , A61K31/7115 , A61K31/7125 , A61K45/06 , C12N2310/17 , C12N2310/31 , C12N2310/317 , C12N2310/321 , C12N2310/3341 , C12N2310/336 , C12N2310/51 , C12N2310/52 , Y02A50/401 , Y02A50/411 , Y02A50/414 , A61K2300/00
摘要： The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
-
公开(公告)号：US08853375B2
公开(公告)日：2014-10-07
申请号：US12192432
申请日：2008-08-15
CPC分类号： A61K31/711 , A61K9/0014 , A61K9/0019 , A61K9/0031 , A61K9/0034 , A61K9/0043 , A61K9/0048 , A61K9/0056 , A61K9/0073 , A61K2039/55561 , Y02A50/401 , Y02A50/412 , Y02A50/414
摘要： The invention relates to TLR9 antagonist compounds and their therapeutic or prophylactic use. The invention provides novel immune regulatory oligonucleotides and immunomers as antagonist of TLRs and methods of use thereof. These immune regulatory oligonucleotides have unique sequences that suppress, without completely ablating, TLR-mediated signaling in response to a TLR ligand or TLR signaling agonist. The methods may have use in the prevention and treatment of autoimmunity, inflammation, inflammatory bowel disease, lupus, allergy, asthma, infection, sepsis, cancer and immunodeficiency.
摘要翻译： 本发明涉及TLR9拮抗剂化合物及其治疗或预防用途。 本发明提供新的免疫调节寡核苷酸和作为TLR拮抗剂的免疫体及其使用方法。 这些免疫调节寡核苷酸具有独特的序列，其能够在不完全消除TLR介导的TLR配体或TLR信号激动剂的信号传导的情况下抑制。 该方法可用于预防和治疗自身免疫，炎症，炎性肠病，狼疮，过敏，哮喘，感染，败血症，癌症和免疫缺陷。
-
6.发明授权Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes 有权通过位置化学变化调节免疫刺激性寡核苷酸类似物的免疫刺激活性公开(公告)号：US08716253B2
公开(公告)日：2014-05-06
申请号：US10694075
申请日：2003-10-27
申请人： Ekambar R. Kandimalla , Qiuyan Zhao , Dong Yu , Sudhir Agrawal
发明人： Ekambar R. Kandimalla , Qiuyan Zhao , Dong Yu , Sudhir Agrawal
CPC分类号： C12N15/117 , A61K31/7088 , A61K31/7115 , A61K2039/55561 , C07H21/00 , C12N2310/18 , C12N2310/3125 , C12N2310/317 , C12N2310/318 , C12N2310/32 , C12N2310/321 , C12N2310/33 , C12N2310/334 , C12N2310/336 , C12N2310/3521
摘要： The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
摘要翻译： 本发明涉及在免疫治疗应用中寡核苷酸或寡核苷酸类似物作为免疫刺激剂的治疗用途。 本发明提供了增强由免疫刺激性寡核苷酸化合物引起的免疫应答的方法。
-
公开(公告)号：US20130142778A1
公开(公告)日：2013-06-06
申请号：US13072017
申请日：2011-03-25
申请人： SUDHIR AGRAWAL , EKAMBAR KANDIMALLA , MALLIKARJUNA PUTTA , Ireneusz Nowak , Nicola LaMonica , Weiwen Jiang , Michael Reardon , Tao Lan
发明人： SUDHIR AGRAWAL , EKAMBAR KANDIMALLA , MALLIKARJUNA PUTTA , Ireneusz Nowak , Nicola LaMonica , Weiwen Jiang , Michael Reardon , Tao Lan
IPC分类号： C12N15/113 , A61K39/35 , A61K39/395 , A61K38/02 , A61K31/7088 , A61K39/00
CPC分类号： C12N15/113 , A61K31/7088 , A61K31/7105 , A61K31/712 , A61K31/713 , A61K38/02 , A61K39/00 , A61K39/35 , A61K39/395 , A61K45/06 , C12N15/111 , C12N15/1138 , C12N2310/113 , C12N2310/14 , C12N2310/317 , C12N2310/318 , C12N2310/344 , C12N2310/50 , C12N2310/51 , C12N2310/52 , C12N2320/30
摘要： The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.
摘要翻译： 本发明人已经研究了提供更有效的miRNA阻断化合物的方法。 本发明人已经发现了惊人地改善miRNA阻断分子的功效的新结构特征。 这些特征包括多个3'末端的存在和在5'端的接头。 令人惊讶的是，这些特征以降低化合物生物学不稳定性的方式提高了基因表达阻断化合物的功效。 更令人惊奇的是，这种效应已被发现适用于基于DNA和RNA的寡核苷酸类化合物，并且应用于传统的反义和RNAi技术。
-
公开(公告)号：US08426375B2
公开(公告)日：2013-04-23
申请号：US12140334
申请日：2008-06-17
申请人： Ekambar Kandimalla , Daqing Wang , Yukui Li , Dong Yu , FuGang Zhu , Lakshmi Bhagat , Sudhir Agrawal
发明人： Ekambar Kandimalla , Daqing Wang , Yukui Li , Dong Yu , FuGang Zhu , Lakshmi Bhagat , Sudhir Agrawal
CPC分类号： A61K48/00 , A61K31/7088 , A61K39/0008 , A61K2039/55561 , Y02A50/401
摘要： The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
-
公开(公告)号：US08361986B2
公开(公告)日：2013-01-29
申请号：US13156140
申请日：2011-06-08
申请人： Ekambar R. Kandimalla , Mallikarjuna Putta , Daqing Wang , Dong Yu , Lakshmi Bhagat , Sudhir Agrawal
发明人： Ekambar R. Kandimalla , Mallikarjuna Putta , Daqing Wang , Dong Yu , Lakshmi Bhagat , Sudhir Agrawal
CPC分类号： A61K31/711 , A61K39/39
摘要： The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles.
摘要翻译： 本发明涉及可用于调节Toll样受体（TLR）介导的免疫应答的合成化学组合物。 特别地，本发明涉及产生独特细胞因子和趋化因子分布的Toll样受体9（TLR9）的激动剂。
-
10.发明授权Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 有权用于TLR7和TLR8的稳定免疫调节RNA（SIMRA）化合物公开(公告)号：US08106173B2
公开(公告)日：2012-01-31
申请号：US11697422
申请日：2007-04-06
申请人： Ekambar R. Kandimalla , Tao Lan , Yukui Li , Dong Yu , Daqing Wang , Mallikarjuna Reddy Putta , Sudhir Agrawal
发明人： Ekambar R. Kandimalla , Tao Lan , Yukui Li , Dong Yu , Daqing Wang , Mallikarjuna Reddy Putta , Sudhir Agrawal
CPC分类号： C07K14/665 , A61K31/713 , A61K39/0005 , A61K39/395 , A61K39/3955 , C12N15/117 , C12N2310/17 , C12N2310/315 , C12N2310/318 , C12N2310/3183 , C12N2310/321 , C12N2310/33 , C12N2310/331 , C12N2310/336 , C12N2310/3521
摘要： The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
摘要翻译： 本发明涉及稳定的寡核糖核苷酸作为免疫治疗应用的免疫调节剂的治疗用途。 具体地，本发明提供具有改进的核酸酶和核糖核酸酶稳定性的基于RNA的寡核糖核苷酸，并且通过TLR7和/或TLR8具有免疫调节活性。
-
-
-
-
-
-
-
-
-
搜索结果
134 条记录 (耗时 0.039 秒)
